Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Maurel

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Investigational New Drugs|October 1, 2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD studyM Martin-Richard, R Gallego, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trialU B Patel, G Brown, I Machado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group studyA Custodio, J Moreno-Rubio, J Aparicio, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Frontiers in Molecular Biosciences|June 2, 2023
Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technologyL Pedrosa, I K Araujo, M Cuatrecasas, et al.
British Journal of Cancer|August 9, 2017
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)J Mora, A Castañeda, S Perez-Jaume, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Investigational New Drugs|October 1, 2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD studyM Martin-Richard, R Gallego, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trialU B Patel, G Brown, I Machado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2015
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†C Fernandez-Martos, X Garcia-Albeniz, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group studyA Custodio, J Moreno-Rubio, J Aparicio, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Frontiers in Molecular Biosciences|June 2, 2023
Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technologyL Pedrosa, I K Araujo, M Cuatrecasas, et al.
British Journal of Cancer|August 9, 2017
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)J Mora, A Castañeda, S Perez-Jaume, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Pageof 9